NATCO Pharma reported a steady performance in its Q2 FY26 numbers, with a mix of moderate revenue growth and softer profitability when compared to the same period last year. The company’s consolidated revenue from operations for the quarter stood at ₹1,363 crore, slightly lower than ₹1,371 crore recorded in Q2 FY25, marking a 0.6% decline year-on-year.
Including other income, the total income for the quarter came in at ₹1,463 crore, almost flat when compared with ₹1,435 crore last year, reflecting a 2% YoY increase supported largely by higher other income.
On the expense front, total expenses rose to ₹849 crore, compared with ₹617 crore in the corresponding quarter last year. This represents a significant increase of about 37.5% YoY, driven mainly by higher employee costs, depreciation, and a notable jump in other expenses.
EBITDA for the quarter came in at ₹579 crore, down from ₹804 crore in the previous year, marking a 28% YoY decline. Operating margins also compressed notably, dropping to 42.5% compared with 58.6% last year, reflecting the impact of higher costs across multiple fronts.
Profit before tax for the quarter came in at ₹614 crore, a decline from ₹818 crore last year, translating to a 24.9% YoY drop. Finally, the bottom line for Q2 FY26 stood at ₹518 crore, compared with ₹677 crore in Q2 FY25, reflecting a 23.5% year-on-year decline in net profit.
